- Home
- IONR vs CRVS Comparison
IONR vs CRVS Comparison
Compare IONR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- CRVS
- Stock Information
- Founded
- IONR 2001
- CRVS 2014
- Country
- IONR Australia
- CRVS United States
- Employees
- IONR N/A
- CRVS N/A
- Industry
- IONR
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- CRVS Health Care
- Exchange
- IONR Nasdaq
- CRVS Nasdaq
- Market Cap
- IONR 171.1M
- CRVS 161.4M
- IPO Year
- IONR N/A
- CRVS 2016
- Fundamental
- Price
- IONR $4.20
- CRVS $5.08
- Analyst Decision
- IONR
- CRVS Buy
- Analyst Count
- IONR 0
- CRVS 3
- Target Price
- IONR N/A
- CRVS $5.75
- AVG Volume (30 Days)
- IONR 8.7K
- CRVS 385.2K
- Earning Date
- IONR 01-01-0001
- CRVS 11-05-2024
- Dividend Yield
- IONR N/A
- CRVS N/A
- EPS Growth
- IONR N/A
- CRVS N/A
- EPS
- IONR N/A
- CRVS N/A
- Revenue
- IONR N/A
- CRVS N/A
- Revenue This Year
- IONR N/A
- CRVS N/A
- Revenue Next Year
- IONR N/A
- CRVS N/A
- P/E Ratio
- IONR N/A
- CRVS N/A
- Revenue Growth
- IONR N/A
- CRVS N/A
- 52 Week Low
- IONR $2.90
- CRVS $1.05
- 52 Week High
- IONR $6.50
- CRVS $5.19
- Technical
- Relative Strength Index (RSI)
- IONR 57.27
- CRVS 73.92
- Support Level
- IONR $3.76
- CRVS $3.90
- Resistance Level
- IONR $4.48
- CRVS $4.75
- Average True Range (ATR)
- IONR 0.28
- CRVS 0.36
- MACD
- IONR 0.03
- CRVS 0.04
- Stochastic Oscillator
- IONR 51.68
- CRVS 93.44
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S. based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).